Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Jong Yoon Lee 3 Articles
Exploring the impact of capsule endoscopy in Kazakhstan: a significant milestone
Jong Yoon Lee
Kosin Med J. 2024;39(3):151-152.   Published online September 9, 2024
DOI: https://doi.org/10.7180/kmj.24.134
  • 431 View
  • 14 Download
PDFPubReader   ePub   
Exploring the nexus between obesity, metabolic syndrome, and colorectal cancer
Jong Yoon Lee
Kosin Med J. 2024;39(1):18-25.   Published online March 12, 2024
DOI: https://doi.org/10.7180/kmj.24.107
  • 1,974 View
  • 50 Download
  • 1 Citations
Abstract PDFPubReader   ePub   
The increasing global prevalence of obesity and metabolic syndrome (MetS) is strongly associated with the incidence of colorectal cancer (CRC). Obesity and MetS detrimentally impact the treatment outcomes of CRC and share similar mechanisms that contribute to the development of CRC. Increased insulin resistance in patients with obesity is linked to CRC, and altered levels of sex hormones and adipokines affect cell growth and inflammation. Obesity and MetS also alter the gut microbiome. Bile acids, which are crucial for lipid metabolism, are elevated in patients with obesity. Moreover, specific bile acids are associated with colonic damage, inflammation, and the development of CRC. Obesity and MetS increase the risk of postoperative complications and affect the response to chemotherapy. The promotion of weight loss and the resolution of MetS can reduce the occurrence of CRC and increase treatment efficacy. Therefore, it is imperative to implement appropriate management strategies to address obesity and MetS with the aim of improving the prognosis and reducing the incidence of CRC. Moreover, additional research should be conducted to determine the optimal timing for tailored CRC screening in patients with obesity or MetS. In this review, we explore the impact of obesity and MetS on the development of CRC and examine potential strategies to mitigate CRC risk in individuals with obesity and MetS.

Citations

Citations to this article as recorded by  
  • Colorectal Cancer and Obesity
    Hyeong Ho Jo
    Journal of Digestive Cancer Research.2024; 12(2): 82.     CrossRef
Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report
Minna Kim, Jong Hoon Lee, Jong Yoon Lee
Kosin Med J. 2023;38(4):300-306.   Published online July 28, 2023
DOI: https://doi.org/10.7180/kmj.23.121
  • 1,768 View
  • 31 Download
Abstract PDFPubReader   ePub   
Drug-induced immune thrombocytopenia (DITP) is a very rare disease, with an estimated annual incidence of 10 cases per million. Oxaliplatin and irinotecan are widely used as chemotherapy for high-risk stage II and III colorectal cancer, and DITP has been reported to occur in patients using those agents. To treat unresectable metastatic colorectal cancer, bevacizumab is used in combination with oxaliplatin or irinotecan, and there have been a few reports of DITP cases in patients receiving that regimen. In this report, we describe a 68-year-old male patient with metastatic colon cancer (KRAS mutant type) to the liver and lung who developed acute immune-mediated thrombocytopenia due to bevacizumab-FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) therapy. During treatment, he showed purpura in his lower extremities on 21st cycle day 2. Lab work revealed a platelet count of less than 2,000/mL, reflecting a decrease from 135,000/mL at the start of the cycle 1 day prior. He did not have any other types of cytopenia or significant changes in laboratory findings. We diagnosed DITP due to bevacizumab-FOLFOX, and the patient did not show isolated thrombocytopenia after switching to Ziv-aflibercept-FOLFIRI (5-fluorouracil, leucovorin, and irinotecan).

KMJ : Kosin Medical Journal
TOP